Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study

详细信息    查看全文

• 作者：Keiko Miyazaki ; Neil P. Jerome ; David J. Collins ; Matthew R. Orton…
• 关键词：Reproducibility of results ; Diffusion magnetic resonance imaging ; Paediatrics ; Medical oncology ; Functional magnetic resonance imaging
• 刊名：European Radiology
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：25
• 期：9
• 页码：2641-2650
• 全文大小：3,528 KB
• 参考文献：1.Norris RE, Adamson PC (2012) Challenges and opportunities in childhood cancer drug development. Nat Rev Cancer 12:776-82
  2.Vassal G, Zwaan CM, Ashley D, Le Deley MC, Hargrave D, Blanc P et al (2013) New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol 14:e117–e124
  3.Boklan J (2006) Little patients, losing patience: pediatric cancer drug development. Mol Cancer Ther 5:1905-908
  4.Chang Y-C, Yu C-J, Chen C-M, Hu F-C, Hsu H-H, Tseng W-YI et al (2012) Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin. J Magn Reson Imaging JMRI 36:387-96
  5.Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES et al (2012) Changes in tumour blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory a. Gynecol Oncol 126:375-80
  6.De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J et al (2012) Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer 106:1926-933
  7.Desar IME, Ter Voert EGW, Hambrock T, Van Asten JJ, Van Spronsen DJ, Mulders PF et al (2011) Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging Off Publ Int Cancer Imaging Soc 11:259-65
  8.Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y et al (2012) Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumour effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer 130:2359-365
  9.Jain R, Scarpace LM, Ellika S, Torcuator R, Schultz LR, Hearshen D et al (2010) Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neuro-Oncol 96:423-31
  10.Koh D-M, Blackledge M, Collins DJ, Padhani AR, Wallace T, Wilton B et al (2009) Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 19:2728-738
  11.Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR et al (2011) Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer 47:997-005
  12.Messiou C, Orton M, Collins DJ, Morgan VA, Mears D, Ghiorghiu D et al (2012) Advanced solid tumours treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity 1. Radiology 265(2):426-6PubMed View Article
  13.Miyazaki K, Orton M, Davidson R (2012) Neuroendocrine tumour liver metastases: use of dynamic contrast-enhanced MR imaging to monitor and predict radiolabeled octreotide therapy response. Radiology 263:139-48
  14.O’Connor JPB, Rose CJ, Jackson A, Watson Y, Cheung S, Maders F et al (2011) DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer 105:139-45
  15.Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X et al (2012) Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neuro-Oncol 108:491-98
  16.Yoo DS, Kirkpatrick JP, Craciunescu O, Broadwater G, Peterson BL, Carroll MD et al (2012) Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer. Clin Cancer Res Off J Am Assoc Cancer Res 18:1404-414
  17.Yopp A, Schwartz L, Kemeny N (2011) Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 18:2192-199
  18.Miyazaki K, D’Arcy JA, Orton MR, Koh D-M, Collins DJ, Leach MO (2011) Improved T1 quantification using post-Gd contrast variable flip angle data. International Society of Magnetic Resonance in Medicine. p 1092
  19.De Bruin P, Versluis M, Yusuf E, Reignierse M, Watt I, Van Osch M (2010) Accuracy of T1-Fitting for Pharmacokinetic Analysis of Dynamic Contrast-Enhanced MRI. International Society of Magnetic Resonance in Medicine. p 1720
  20.Miyazaki K, Orton MR, Collins DJ, d’Arcy JA, Wallace T, Moreno L et al (2013) Preliminary analysis of arterial input function derived from dynamic contrast enhanced MRI in children with cancer. International Society of Magnetic Resonance in Medicine. p 720
  21.Orton MR, Collins DJ, Messiou C, Castellano E, Tessier J, Spratt S et al (2010) A New Vascular Impulse Response Fun
• 作者单位：Keiko Miyazaki (1)
  Neil P. Jerome (1)
  David J. Collins (1)
  Matthew R. Orton (1)
  James A. d’Arcy (1)
  Toni Wallace (2)
  Lucas Moreno (3) (4) (5)
  Andrew D. J. Pearson (3) (5)
  Lynley V. Marshall (3) (5)
  Fernando Carceller (3) (5)
  Martin O. Leach (1)
  Stergios Zacharoulis (3) (5)
  Dow-Mu Koh (2)
  
  1. Cancer Research UK Cancer Imaging Centre at The Institute of Cancer Research, London, SM2 5NG, UK
  2. Department of Radiology, Royal Marsden Hospital, London, England, UK
  3. Paediatric Drug Development Team, Divisions of Cancer Therapeutics and Clinical Studies, The Institute of Cancer Research, London, SM2 5NG, UK
  4. Clinical Research Programme, Spanish National Cancer Research Centre (CNIO), Melchor Fernandez Almagro 3, 28029, Madrid, Spain
  5. Paediatric Drug Development Unit, Children and Young People’s Unit, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, SM2 5PT, UK
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Imaging and Radiology
  Diagnostic Radiology
  Interventional Radiology
  Neuroradiology
  Ultrasound
  Internal Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1084

文摘

Objectives The objectives are to examine the reproducibility of functional MR imaging in children with solid tumours using quantitative parameters derived from diffusion-weighted (DW-) and dynamic contrast enhanced (DCE-) MRI. Methods Patients under 16-years-of age with confirmed diagnosis of solid tumours (n--7) underwent free-breathing DW-MRI and DCE-MRI on a 1.5?T system, repeated 24?hours later. DW-MRI (6 b-values, 0-1000?sec/mm2) enabled monoexponential apparent diffusion coefficient estimation using all (ADC0-1000) and only ?00?sec/mm2 (ADC100-1000) b-values. DCE-MRI was used to derive the transfer constant (Ktrans), the efflux constant (kep), the extracellular extravascular volume (ve), and the plasma fraction (vp), using a study cohort arterial input function (AIF) and the extended Tofts model. Initial area under the gadolinium enhancement curve and pre-contrast T1 were also calculated. Percentage coefficients of variation (CV) of all parameters were calculated. Results The most reproducible cohort parameters were ADC100-1000 (CV--.26?%), pre-contrast T1 (CV--.21?%), and Ktrans (CV--5.23?%). The ADC100-1000 was more reproducible than ADC0-1000, especially extracranially (CV--.40?% vs. 2.78?%). The AIF (n--) derived from this paediatric population exhibited sharper and earlier first-pass and recirculation peaks compared with the literature’s adult population average. Conclusions Free-breathing functional imaging protocols including DW-MRI and DCE-MRI are well-tolerated in children aged 6 - 15 with good to moderate measurement reproducibility. Key Points -Diffusion MRI protocol is feasible and well-tolerated in a paediatric oncology population. -DCE-MRI for pharmacokinetic evaluation is feasible and well tolerated in a paediatric oncology population. -Paediatric arterial input function (AIF) shows systematic differences from the adult population-average AIF. -Variation of quantitative parameters from paired functional MRI measurements were within 20?%.